180 related articles for article (PubMed ID: 1715220)
1. On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site.
Keijer J; Linders M; Wegman JJ; Ehrlich HJ; Mertens K; Pannekoek H
Blood; 1991 Sep; 78(5):1254-61. PubMed ID: 1715220
[TBL] [Abstract][Full Text] [Related]
2. Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties.
Ehrlich HJ; Gebbink RK; Keijer J; Linders M; Preissner KT; Pannekoek H
J Biol Chem; 1990 Aug; 265(22):13029-35. PubMed ID: 1695900
[TBL] [Abstract][Full Text] [Related]
3. The inhibition of tissue type plasminogen activator by plasminogen activator inhibitor-1. The effects of fibrinogen, heparin, vitronectin, and lipoprotein(a).
Edelberg JM; Reilly CF; Pizzo SV
J Biol Chem; 1991 Apr; 266(12):7488-93. PubMed ID: 1708387
[TBL] [Abstract][Full Text] [Related]
4. Vitronectin governs the interaction between plasminogen activator inhibitor 1 and tissue-type plasminogen activator.
Keijer J; Ehrlich HJ; Linders M; Preissner KT; Pannekoek H
J Biol Chem; 1991 Jun; 266(16):10700-7. PubMed ID: 1709939
[TBL] [Abstract][Full Text] [Related]
5. Identification of tissue-type plasminogen activator-specific plasminogen activator inhibitor-1 mutants. Evidence that second sites of interaction contribute to target specificity.
Sherman PM; Lawrence DA; Verhamme IM; Paielli D; Shore JD; Ginsburg D
J Biol Chem; 1995 Apr; 270(16):9301-6. PubMed ID: 7721851
[TBL] [Abstract][Full Text] [Related]
6. Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin.
Ehrlich HJ; Keijer J; Preissner KT; Gebbink RK; Pannekoek H
Biochemistry; 1991 Jan; 30(4):1021-8. PubMed ID: 1703436
[TBL] [Abstract][Full Text] [Related]
7. Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation.
Kost C; Stüber W; Ehrlich HJ; Pannekoek H; Preissner KT
J Biol Chem; 1992 Jun; 267(17):12098-105. PubMed ID: 1376317
[TBL] [Abstract][Full Text] [Related]
8. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2.
Thorsen S; Philips M; Selmer J; Lecander I; Astedt B
Eur J Biochem; 1988 Jul; 175(1):33-9. PubMed ID: 3136015
[TBL] [Abstract][Full Text] [Related]
9. The irreversible inhibition of urokinase, kidney-cell plasminogen activator, plasmin and beta-trypsin by 1-(N-6-amino-n-hexyl)carbamoylimidazole.
Walker B; Elmore DT
Biochem J; 1984 Jul; 221(1):277-80. PubMed ID: 6235806
[TBL] [Abstract][Full Text] [Related]
10. Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix.
Ehrlich HJ; Gebbink RK; Preissner KT; Keijer J; Esmon NL; Mertens K; Pannekoek H
J Cell Biol; 1991 Dec; 115(6):1773-81. PubMed ID: 1721912
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells.
Coleman PL; Patel PD; Cwikel BJ; Rafferty UM; Sznycer-Laszuk R; Gelehrter TD
J Biol Chem; 1986 Mar; 261(9):4352-7. PubMed ID: 2936742
[TBL] [Abstract][Full Text] [Related]
12. Production of proteases type plasminogen activator and their inhibitor in cornea.
Mirshahi M; Mirshahi S; Soria C; Soria J; Thomaidis A; Pouliquen Y; Faure JP
Biochem Biophys Res Commun; 1989 May; 160(3):1021-5. PubMed ID: 2499321
[TBL] [Abstract][Full Text] [Related]
13. Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells.
Lawrence D; Strandberg L; Grundström T; Ny T
Eur J Biochem; 1989 Dec; 186(3):523-33. PubMed ID: 2514093
[TBL] [Abstract][Full Text] [Related]
14. Combinatorial mutagenesis of the reactive site region in plasminogen activator inhibitor I.
York JD; Li P; Gardell SJ
J Biol Chem; 1991 May; 266(13):8495-500. PubMed ID: 2022663
[TBL] [Abstract][Full Text] [Related]
15. Rivaroxaban and apixaban induce clotting factor Xa fibrinolytic activity.
Carter RLR; Talbot K; Hur WS; Meixner SC; Van Der Gugten JG; Holmes DT; Côté HCF; Kastrup CJ; Smith TW; Lee AYY; Pryzdial ELG
J Thromb Haemost; 2018 Nov; 16(11):2276-2288. PubMed ID: 30176116
[TBL] [Abstract][Full Text] [Related]
16. A cyclopeptidic suicide substrate preferentially inactivates urokinase-type plasminogen activator.
Reboud-Ravaux M; Vilain AC; Boggetto N; Maillard J; Favreau C; Xie J; Mazaleyrat JP; Wakselman M
Biochem Biophys Res Commun; 1991 Jul; 178(1):352-9. PubMed ID: 1829886
[TBL] [Abstract][Full Text] [Related]
17. Amiloride selectively inhibits the urokinase-type plasminogen activator.
Vassalli JD; Belin D
FEBS Lett; 1987 Apr; 214(1):187-91. PubMed ID: 3106085
[TBL] [Abstract][Full Text] [Related]
18. Molecular advances in plasminogen activator inhibitor 1 interaction with thrombin and tissue-type plasminogen activator.
Stoop A; van Meijer M; Horrevoets AJ; Pannekoek H
Trends Cardiovasc Med; 1997 Feb; 7(2):47-51. PubMed ID: 21235863
[TBL] [Abstract][Full Text] [Related]
19. Less pronounced enhancement of thrombin-dependent inactivation of plasminogen activator inhibitor type 1 by low molecular weight heparin compared with unfractionated heparin.
Nakamura R; Umemura K; Hashimmoto H; Urano T
Thromb Haemost; 2006 Apr; 95(4):637-42. PubMed ID: 16601834
[TBL] [Abstract][Full Text] [Related]
20. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]